Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TST001

Phase 2Small molecule

SSuzhou Transcenta Therapeutics Co., Ltd.

TST001 is one of 72 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.

2

Indications

4

Total Trials

2

Active Trials

71

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

Biliary Tract CancerActive, not recruiting

AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Biliary Tract CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

337 competitors in Adenocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Taxol

Taxotere

Cyramza

Iressa

Ellence

Opdivo

Bristol-Myers Squibb

Wellcovorin

GGlaxo Dba Glaxosmithkline

Paraplatin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Advanced or Metastatic Solid Tumors

NCT04396821

Phase 1/2Recruiting

Advanced or Metastatic Solid Tumors

NCT04495296

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors2 trials

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting·SSuzhou Transcenta Therapeutics Co., Ltd.·Phase 1/2·NCT04495296·320 enrolled

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Active, not recruiting·SSuzhou Transcenta Therapeutics Co., Ltd.·Phase 1/2·NCT04396821·150 enrolled

Adenocarcinoma1 trial

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Unknown status·HHenan Cancer Hospital·Phase 1/2·NCT05608785·45 enrolled

Biliary Tract Cancer1 trial

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Completed·SShanghai Zhongshan Hospital·Phase 2·NCT05190575·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TST001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TST001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TST001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Transcenta Therapeutics Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSuzhou Transcenta Therapeutics Co., Ltd.

Related News